| Species |
Human |
| Protein Construction |
DLL4, Humann (Ser27-Pro524)
Accession # Q9NR61 |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Biological Activity |
Immobilized DLL4, Human (Cat.No.: Z03812) at 0.5 μg/ml can bind Anti-DLL4 Antibody. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
54.28 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS, 200 mM Arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the lyophilized product remains stable up to 6 months at -20 °C or below as supplied from date of receipt.
-80°C for 3 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Target Background |
DLL4 is a type I membrane protein in the Delta/Serrate/Lag2 (DSL) family of Notch ligands. It activates NOTCH1 and NOTCH4, and plays a role in angiogenesis by negatively regulating endothelial cell proliferation and migration, as well as angiogenic sprouting. It is essential for retinal progenitor proliferation and is required for suppressing rod fates in late retinal progenitors, as well as for proper generation of other retinal cell types. Additionally, during spinal cord neurogenesis, it inhibits V2a interneuron fate. |
| Synonyms |
DLL4; MGC126344; notch ligand DLL4; Delta4; Delta-like 4 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
